跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
solid tumor therapy (1)
首页
药物
solid tumor therapy (1)
solid tumor therapy (1)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CANCER THERAPY INVOLVING CAR-ENGINEERED T-CELLS AND PARVOVIRUS H-1
申请人: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS / UNIV HEIDELBERG
优先权: 2021
CN
EP
US
WO
5 件公开
Method of treating cancer by co-administration of anticancer agents
申请人: ASTELLAS PHARMA INC
优先权: 2007
US
5 件公开
Combination therapy for cancer treatment
申请人: IPSEN BIOPHARM LTD
优先权: 2015
CN
US
4 件公开
METHOD TO GENERATE IMPROVING CAR-T CELLS
申请人: INST NAT SANTE RECH MED
优先权: 2022
EP
US
WO
3 件公开
TREATMENT OF SOLID TUMORS WITH A REGIMEN OF TARGETED RADIONUCLIDE THERAPY AND GENETICALLY ENGINEERED IMMUNE CELL THERAPIES
申请人: WISCONSIN ALUMNI RES FOUND
优先权: 2023
CN
EP
WO
3 件公开
ISOLATED TCR AND USE THEREOF
申请人: SHANGHAI GENERAL HOSPITAL
优先权: 2023
CN
EP
WO
3 件公开
ANTI-PD-1-BASED TREATMENT BEFORE AND AFTER SURGERY
申请人: BEONE MEDICINES I GMBH
优先权: 2023
CN
EP
WO
3 件公开
ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER
申请人: UNIV LELAND STANFORD JUNIOR
优先权: 2017
CN
EP
3 件公开
COMBINATION THERAPY
申请人: DHINGRA KAPIL
优先权: 2011
CN
US
2 件公开
COMBINATION OF ANTI-PD-1 ANTIBODIES AND RADIATION TO TREAT CANCER
申请人: REGENERON PHARMA
优先权: 2016
US
WO
2 件公开
第 1 / 7 页
上一页
下一页
药物
反馈